Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever

被引：15

作者：

Tsao, Che-Kai ^{[1
]}

Galsky, Matthew D. ^{[1
]}

Oh, William K. ^{[1
]}

机构：

[1] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY USA

来源：

EUROPEAN UROLOGY | 2016年 / 70卷 / 05期

关键词：

ANDROGEN-DEPRIVATION THERAPY; FEBRILE NEUTROPENIA; PREDICTIVE FACTORS; CHEMOTHERAPY;

D O I：

10.1016/j.eururo.2016.06.041

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

First-line docetaxel treatment for metastatic castration-sensitive prostate cancer is associated with higher rates of neutropenic fever compared with those with castration-resistant disease, and prophylactic granulocyte colony-stimulating factor should be considered in those harboring risk factors for developing neutropenia.

引用

页码：707 / +

页数：3

共 50 条

[1] Docetaxel for hormone-sensitive metastatic prostate cancer
Baker, Holly
LANCET ONCOLOGY, 2015, 16 (09): : E432 - E432
[2] Docetaxel Improves Survival in Metastatic Hormone-Sensitive Prostate Cancer
Schuyler, Devon
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (09) : 549 - 549
[3] Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?
Kartolo, Adi
Tannock, Ian F.
Badillo, Francisco E. Vera
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (31) : 3573 - +
[4] Audit of febrile neutropenic (FN) episodes in men receiving docetaxel for hormone-sensitive metastatic prostate cancer (HSMPC)
Raby, S.
Mahil, J.
Hughes, C.
Lyons, J.
Patel, K.
Elliott, T.
Conroy
CLINICAL ONCOLOGY, 2016, 28 : S8 - S8
[5] Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
de Groot, Ietsen
Brinkman, Ithamar
Luijendijk-de Bruin, Daphne
Poort, Sharon
van Rooijen, Johan M.
EUROPEAN UROLOGY OPEN SCIENCE, 2021, 33 : 48 - 55
[6] Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice
Lendorf, Maria Elisabeth
Petersen, Peter Meidahl
Svendsen, Andrea Steen
Lindberg, Henriette
Brasso, Klaus
EUROPEAN UROLOGY OPEN SCIENCE, 2021, 24 : 25 - 33
[7] Metastatic hormone-sensitive prostate cancer
Gravis, Gwenaelle
Salem, Naji
Walz, Jochen
BULLETIN DU CANCER, 2015, 102 (01) : 57 - 64
[8] Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer
Lage, Daniel E.
Michaelson, Dror M.
Lee, Richard J.
Greer, Joseph A.
Temel, Jennifer S.
Sweeney, Christopher
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[9] Early docetaxel-resistance in metastatic hormone-sensitive prostate cancer.
Bukhari, Nedal
Potvin, Kvica R.
Ernst, D. Scott
Sax, Lori
Winquist, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
[10] Is Docetaxel Chemotherapy a New Standard of Care for Metastatic Hormone-Sensitive Prostate Cancer?
Liaw, Bobby C.
Oh, William K.
AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2015, 11 (09) : 17 - 20

← 1 2 3 4 5 →